fbpx

Dry Eye Rescue Is Offering Friends Of MDA A 20% Discount On All Products To Help With Your Eye Conditions

Click Here To Save Now

Jan 31, 2025

Opening our eyes to the impact of preservatives

By Elyse Rayborn, OD, MBA, FAAO
Chris Lievens, OD, MS, FAAO, FNAP
Optometry Times JournalJanuary/February digital edition 2025

Preservatives may disrupt the ocular surface, contributing to poor adherence.

Glaucoma is a leading cause of irreversible blindness worldwide. The pathogenesis of glaucoma is not entirely understood; however, major risk factors are well established and include advancing age, genetic predisposition, and increased intraocular pressure (IOP). The only known modifiable risk factor is IOP. Evidence-based treatments to lower IOP include topical ophthalmic medications, laser procedures, sustained release implants, and/or surgical interventions. The most common approach for managing glaucoma, especially for the primary care optometrist, is IOP-lowering medication.1 Often patients with glaucoma are on multiple topical therapeutic agents to achieve optimal IOP measurements. While effective at lowering IOP, topical medications have historically contained preservatives. Preservatives are detergents used to prolong the shelf life of medications and maintain sterility; however, their presence can also have some adverse effects on the eye and cause challenges for the ocular surface.2

The world’s population is aging, resulting in an increase in the geriatric demographic, leading to a rise in certain diseases, including glaucoma. It is estimated that approximately 3 million Americans are currently being treated for glaucoma and this number is expected to double by 2050.3 The Glaucoma Research Foundation reports a dramatic increase in glaucoma diagnosis in patients over 60 years4; coupled with an estimated life expectancy in the US of 77.5 years,5 this means that most patients with glaucoma are relying on topical antiglaucoma medications for years, if not decades. The risk of developing ocular surface complications increases with the duration of topical therapy use and the number of preserved topical therapies a patient uses. As optometrists, we should be mindful of these ocular surface issues and prescribe with patient compliance, comfort, and quality of life in mind…..

Read more: rb.gy/f6iyfa

Source: Optometry Times

 

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.